<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2216">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05132309</url>
  </required_header>
  <id_info>
    <org_study_id>CP-2021</org_study_id>
    <nct_id>NCT05132309</nct_id>
  </id_info>
  <brief_title>Intestinal Microbiota Composition in Patients With Chronic Pancreatitis and Pancreatic Exocrine Insufficiency</brief_title>
  <official_title>Study of Influence of Chronic Pancreatitis Severity Degree With Possible Complication of Pancreatic External Secretory Insufficiency on Intestinal Microbiota Composition Patterns</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal Research and Clinical Center of Physical-Chemical Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Moscow State University of Medicine and Dentistry</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Federal Research and Clinical Center of Physical-Chemical Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of qualitative and quantitative composition of the intestinal microbiota in&#xD;
      patients with CP; in patients with CP and PEI complication of mild to severe degree; patients&#xD;
      with CP and PEI who underwent surgical intervention on the pancreas. Intergroup comparison of&#xD;
      the microbial compositional characteristics and their analysis. Correction of enzyme&#xD;
      replacement therapy in selected groups of patients with regard to the identified microbial&#xD;
      characteristics. Assessment of the intestinal microbiota composition in dynamics after 6 (+1)&#xD;
      months on the background of allocated therapy&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2020</start_date>
  <completion_date type="Actual">July 1, 2021</completion_date>
  <primary_completion_date type="Actual">July 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Genetic study of fecal samples of patients with CP</measure>
    <time_frame>1 week</time_frame>
    <description>Fecal samples of patients with CP from selected patient groups with/without PEI meet inclusion criteria will undergo 16s rRNA gene sequencing for further comparative intergroup analysis of the obtained data.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Genetic study of fecal samples of patients with CP</measure>
    <time_frame>6 months</time_frame>
    <description>Fecal samples of patients with CP from selected patient groups with/without PEI meet inclusion criteria will undergo 16s rRNA gene sequencing for further comparative intergroup analysis of the obtained data.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Analysis of intestinal microbiota composition of patients with CP receiving 40,000 units of pancreatin per meal per day</measure>
    <time_frame>6 months</time_frame>
    <description>Analysis of intestinal microbiota composition of patients with CP from selected patient groups with/without PEI receiving adequate dosage of enzyme replacement therapy: 40,000 units of pancreatin per meal per day</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Analysis of intestinal microbiota composition of patients with CP receiving inadequate dosage of pancreatin per meal per day</measure>
    <time_frame>6 month</time_frame>
    <description>Analysis of intestinal microbiota composition of patients with CP from selected patient groups with/without PEI receiving inadequate dosage of enzyme replacement therapy: (less then adequate dosage) of pancreatin per meal per day</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">96</enrollment>
  <condition>Chronic Pancreatitis</condition>
  <condition>Pancreatic Exocrine Insufficiency</condition>
  <arm_group>
    <arm_group_label>Chronic pancreatitis without pancreatic external insufficiency</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Chronic pancreatitis with mild pancreatic external insufficiency</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Chronic pancreatitis with severe pancreatic external insufficiency</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Chronic pancreatitis with severe pancreatic external insufficiency who underwent pancreatic surger</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>enzyme replacement therapy</intervention_name>
    <description>Correction of the previously prescribed dose of enzyme replacement therapy (ERT)/first time selection of ERT according to the severity of pancreatic exocrine insufficiency</description>
    <arm_group_label>Chronic pancreatitis with mild pancreatic external insufficiency</arm_group_label>
    <arm_group_label>Chronic pancreatitis with severe pancreatic external insufficiency</arm_group_label>
    <arm_group_label>Chronic pancreatitis with severe pancreatic external insufficiency who underwent pancreatic surger</arm_group_label>
    <arm_group_label>Chronic pancreatitis without pancreatic external insufficiency</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        primary care clinic&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 to 80 years old; any gender;&#xD;
&#xD;
          -  Chronic pancreatitis etiology: idiopathic, biliary dependent, drug-induced, alcoholic,&#xD;
             dysmetabolic, CP as a consequence of recurrent and severe acute pancreatitis&#xD;
             (postnecrotic);&#xD;
&#xD;
          -  History of confirming diagnostic criteria of CP (in accordance with 1) Clinical&#xD;
             guidelines of the Russian Gastroenterological Association on the diagnosis and&#xD;
             treatment of exocrine pancreatic insufficiency 2018; 2) Clinical guidelines of the&#xD;
             unified European guidelines for gastroenterology, on the diagnosis and therapy of&#xD;
             chronic pancreatitis 2017; 3) Clinical guidelines of the American College of&#xD;
             Gastroenterology 2020);&#xD;
&#xD;
          -  CP diagnosis according to multispiral computed tomography of the abdominal cavity&#xD;
             and/or endoscopic ultrasonography of pancreas: size changes; dilatation of the main&#xD;
             pancreatic duct more than 2 mm; increased echogenicity of the walls, uneven contours&#xD;
             and heterogeneity of the BP parenchyma, concrements or calcification of the&#xD;
             parenchyma;&#xD;
&#xD;
          -  Clinical manifestations of exocrine insufficiency of pancreas: stool disorders&#xD;
             (mushy/liquid stool, number of defecation acts &gt;3 p/day, undigested food remains),&#xD;
             steatorrhea, abdominal distention, nausea/vomiting, weight loss progression with&#xD;
             adequate caloric intake and no other objective reasons of weight loss;&#xD;
&#xD;
          -  Fecal elastase-1 values less than 200 µg/g (for CP groups with EPI) or more than 200&#xD;
             µg/g (for CP group without concomitant EPI);&#xD;
&#xD;
          -  Informed patient consent to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute pancreatitis;&#xD;
&#xD;
          -  Hepatitis, cirrhosis of any etiology;&#xD;
&#xD;
          -  Any acid-dependent diseases requiring immediate or long-term proton pump inhibitor&#xD;
             therapy (PPI): gastroesophageal reflux disease, acute gastroduodenal erosions of any&#xD;
             etiology; Zollinger-Ellison syndrome, etc;&#xD;
&#xD;
          -  Stenosis of pylorys or duodenum;&#xD;
&#xD;
          -  Condition after gastric resection or gastrectomy;&#xD;
&#xD;
          -  Obstructive and autoimmune CP;&#xD;
&#xD;
          -  Mesenteric ischemia syndrome;&#xD;
&#xD;
          -  Any other cause of chronic diarrhea (irritable bowel syndrome with diarrhea&#xD;
             predominance, gluten enteropathy, lactase deficiency, inflammatory bowel disease,&#xD;
             etc.);&#xD;
&#xD;
          -  Concomitant administration of drugs directly affecting exocrine pancreatic secretion&#xD;
             (octreotide);&#xD;
&#xD;
          -  Any concomitant diseases in the stage of decompensation (cardiovascular, renal&#xD;
             failure, diabetes mellitus, etc.);&#xD;
&#xD;
          -  Chronic infectious diseases requiring constant (long-term) supportive therapy,&#xD;
             including HIV infection, etc;&#xD;
&#xD;
          -  Hypersensitivity to pancreatin;&#xD;
&#xD;
          -  Use of pro-, pre-, synbiotics, week prior to inclusion in this study;&#xD;
&#xD;
          -  Use of antibiotics within 4 weeks prior to inclusion in this study;&#xD;
&#xD;
          -  Pregnancy and lactation;&#xD;
&#xD;
          -  Use of prohibited concomitant therapy during the study: pro-, pre-, synbiotics,&#xD;
             including dietary fiber preparations and lactulose, as well as antibiotics, intestinal&#xD;
             antiseptics, loperamide, intestinal sorbents.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>23 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elena Ilina, Prof</last_name>
    <role>Study Director</role>
    <affiliation>Federal Research and Clinical Center of Physical-Chemical Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Igor Maev, Prof</last_name>
    <role>Study Director</role>
    <affiliation>Moscow State University of Medicine and Dentistry</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Federal Research and Clinical Center of Physical-Chemical Medicine, Moscow (FRCC PCM)</name>
      <address>
        <city>Moscow</city>
        <zip>117312</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow State University of Medicine and Dentistry</name>
      <address>
        <city>Moscow</city>
        <zip>127473</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 30, 2021</study_first_submitted>
  <study_first_submitted_qc>November 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2021</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
    <mesh_term>Pancreatitis, Chronic</mesh_term>
    <mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

